Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment

Status Terminated

Clinical Trial Summary

This is an open label, investigator-sponsored, pilot study. Subjects agreeing to participate in the study and meeting the eligibility criteria assessed at the screening visit will be enrolled in the study. The length of time between screening and treatment will last between 0 days to a maximum of 12 weeks. Subjects who enter the screening phase during a cluster headache episode and meet the study eligibility criteria can immediately enter the treatment phase and may opt to treat their cluster headache episode in the clinic. Subjects who are not in a cluster headache episode, who meet initial screening eligibility criteria, can remain in the screening phase for up to 12 weeks until their next cluster episode begins. Upon initiation of a cluster headache episode, subjects will enter the treatment period. Subjects will be trained on the proper use of the hand-held dispenser containing carbon dioxide (CO2 )calibrated to deliver 0.5 standard liters per minute (SLPM). This dispenser will be provided for use in the clinic or home. Subjects will be instructed to use the nasal CO2 dispenser, 10 seconds/nostril, as needed up to 6 times to treat one attack. Each dose must be separated by 3-5 minutes. Subjects should treat only one attack in a 24-hour period. Subjects may treat up to three cluster headache attacks during the treatment phase of this study. One hour after the first dose, subjects can choose to treat with investigator-approved rescue medication. Subjects will be asked to complete an online diary after the completion of the dosing. Diary assessments will collect pain severity, nasal CO2 usage, acute medication usage, satisfaction of treatment, number of cluster attacks, and unusual symptoms. Subjects will be contacted by phone within 3 days of the first use of the nasal CO2 dispenser to assess adverse events (AEs) and medication usage. A total of 25 subjects will enter the treatment period and be instructed to treat up to 3 cluster headaches with nasal CO2. Within 7 days of treating their last cluster headache episode, subjects will return for an end of study visit.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02381795
Study type	Interventional
Source	Cady, Roger, M.D.
Contact
Status	Terminated
Phase	Phase 2
Start date	July 2015
Completion date	April 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05264714` - Cluster Headache Treatment With Rimegepant	Phase 2
Completed	`NCT01677026` - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated	`NCT00203190` - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache	Phase 4
Recruiting	`NCT04570475` - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache	Phase 3
Completed	`NCT04066023` - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches	Phase 2/Phase 3
Withdrawn	`NCT04353505` - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache	Phase 1
Completed	`NCT02019017` - Botox Injection in Treatment of Cluster Headache	Phase 1/Phase 2
Recruiting	`NCT05153876` - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting	`NCT05324748` - Repeated GON Injections in CCH	Phase 3
Completed	`NCT02782533` - DBS of the Third Ventricle for Cluster Headache and Obesity	N/A
Completed	`NCT04179266` - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache	Phase 1/Phase 2
Recruiting	`NCT04406259` - Atrioventricular Block and Cluster Headache (SEVA)	Phase 4
Recruiting	`NCT06206772` - Resting State Functional Connectivity in Cluster Headache
Recruiting	`NCT03944876` - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache	Phase 3
Not yet recruiting	`NCT05857098` - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting	`NCT02910323` - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated	`NCT00458770` - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks	N/A
Completed	`NCT00662935` - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)	N/A
Active, not recruiting	`NCT03511846` - Pain Biomarker Study	Phase 1
Completed	`NCT00184587` - Prophylactic Treatment of Episodic Cluster Headache	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms